



**Press release
For immediate distribution**

Cisbio releases a new HTRF® assay offer dedicated to the cGas/STING pathway.

Cisbio extends its assay portfolio for immuno-oncology drug discovery with breakthrough biochemical and cell-based STING assays.

Codolet, France. January 30th, 2019. Cisbio announces the launch of 3 novel HTRF® STING assays to identify and characterize compounds targeting the STING protein. Recent work in immuno-oncology research has demonstrated that the STING signaling pathway is closely involved in enhancing the cross-priming of cytotoxic T-cells by dendritic cells, a process that boosts innate immune signaling and subsequently improves anti-tumor immune response. These new assays come in addition to three important assays released last year: TBK1, IRF3 and IFN β .

The new STING HTRF-based offer includes: i) a biochemical human STING binding assay which enables the screening and characterization of STING binders, ii) cell-based phospho- and total STING assays to investigate the mode of action of STING binders in a physiological cell-based context. The Cisbio team is also able to provide STING custom profiling services to its customers.

"STING has been receiving increased scrutiny from the scientific community for its potential to stimulate innate and prime adaptive immunity, thus showing promise as a druggable pathway," declared Nicolas Pierre, Head of Global Marketing at Cisbio. "We have rapidly taken up this demand to develop a full series of assays that provide meaningful benefits to researchers exploring the role of STING in immuno-oncology."

With its latest product launch, Cisbio further strengthens its leadership in assays for immuno-oncology research, and supplements its already existing immune checkpoint and cell signaling assay portfolio with a highly innovative set of tools for this pivotal pathway.

About Cisbio (www.cisbio.com)

Cisbio develops and markets products and technologies used for life science research and in vitro diagnostics. With its proprietary technology, HTRF®, the company is a leader in homogeneous fluorescence detection methods and offers first class assays and services for drug discovery researchers. In addition, Cisbio provides a broad range of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies, as well as metabolic and auto-immune diseases.

Based in Codolet, France, Cisbio owns facilities in Bedford, MA, U.S.A., Shanghai, China, and Tokyo, Japan, and also markets its global offer through a network of distributors.

Media contacts:

Cisbio: François Degorce, +33 4 66 79 19 31, fdegorce@cisbio.com